Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX53 + serplulimab + bevacizumab biosimilar versus placebo + serplulimab + bevacizumab in untreated advanced hepatocellular carcinoma
CTR20241634Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Aug 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HLX53 in hepatocellular carcinoma (HCC), sponsored by HyBioPharma. Started Aug 2024; status: active.
02
Drugs
HLX53
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20241634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241634.